Phio Pharmaceuticals Corp.
Last updated September 27, 2026
Organization details
- Legal name
- Phio Pharmaceuticals Corp.
- Former names
- RXi Pharmaceuticals Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- King of Prussia
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PHIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001533040
- EIN
- 45-3215903
Board of directors
-
Curtis Lockshin · DirectorSince 2023
-
David H. Deming · DirectorSince 2025
-
Geert Cauwenbergh · DirectorSince 2023
-
Jonathan E. Freeman · DirectorSince 2023
-
Patricia A. Bradford · DirectorSince 2023
-
Robert J. Bitterman · Director · Chairman, Pres. & CEOSince 2023
-
Robert L. Ferrara · DirectorSince 2023
-
Ronald Todd Plott · DirectorSince 2026
Chief executives
Robert J. Bitterman
· President & CEO
Dates unknown
Director election results
Annual meeting of September 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
93.7%
-
96.7%
-
96.9%
-
97.1%
-
97.1%
-
97.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $80,900
- 10 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 28, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Grant or award | +400,000 | — | — |
| Sep 28, 2026 | Carson Lisa Cabott Officer (Chief Financial Officer) | Grant or award | +108,000 | — | — |
| Sep 28, 2026 | Ronald Todd Plott Director | Grant or award | +17,000 | — | — |
| Sep 24, 2026 | Patricia A. Bradford Director | Open-market purchase | +6,500 | $1.01 | $6,583 |
| Sep 22, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Open-market purchase | +2,000 | $1.03 | $2,058 |
| Sep 15, 2026 | Patricia A. Bradford Director | Open-market purchase | +12,000 | $1.03 | $12,360 |
| Sep 11, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Shares withheld for tax | −68,550 | $1.03 | $70,607 |
| Sep 11, 2026 | Carson Lisa Cabott Officer (Chief Financial Officer) | Shares withheld for tax | −12,888 | $1.03 | $13,275 |
| Aug 19, 2026 | Ronald Todd Plott Director | Open-market purchase | +15,000 | $1.14 | $17,100 |
| Aug 18, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Open-market purchase | +10,000 | $1.06 | $10,600 |
| Jun 26, 2026 | Robert J. Bitterman Director, Officer (Chairman, Pres. & CEO) | Open-market purchase | +10,000 | $0.99 | $9,900 |
| Feb 5, 2026 | Curtis Lockshin Director | Grant or award | +16,600 | — | — |
| Feb 5, 2026 | Jonathan E. Freeman Director | Grant or award | +16,600 | — | — |
| Feb 5, 2026 | David H. Deming Director | Grant or award | +23,800 | — | — |
| Feb 5, 2026 | Carson Lisa Cabott Officer (Chief Financial Officer) | Grant or award | +47,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.